Table 3.
Vancomycin Serum Concentration Evaluation Based on Goal Level and Nephrotoxic Occurrences
| Secondary Outcomes | Weight-Based (n = 41) | BSA-Based (n = 64) | p value |
|---|---|---|---|
| Serum vancomycin trough concentrations for all patients | |||
| Supratherapeutic, n (%) | 1 (2) | 9 (14) | 0.084 |
| Therapeutic, n (%) | 8 (20) | 12 (19) | >0.99 |
| Subtherapeutic, n (%) | 32 (78) | 43 (67) | 0.27 |
| Serum vancomycin concentrations for overweight and obese patients | n = 15 | n = 12 | |
| Supratherapeutic, n (%) | 1 (7) | 1 (8) | 0.99 |
| Therapeutic, n (%) | 3 (20) | 4 (33) | 0.66 |
| Subtherapeutic, n (%) | 11 (73) | 7 (58) | 0.45 |
| All patients | n = 57 | n = 22 | |
| Nephrotoxic occurrences, n (%) | 4 (7) | 0 (0) | 0.57 |